利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.018 秒)

    Shoehorn
    1.
    外观设计
    Shoehorn 有权

    公开(公告)号：USD1007809S1

    公开(公告)日：2023-12-19

    申请号：US29809839

    申请日：2021-09-30

    申请人： Haiming Chen

    设计人： Haiming Chen

    摘要： FIG. 1 is a front, right and top perspective view of a shoehorn, showing my design.
    FIG. 2 is a front elevation view thereof.
    FIG. 3 is a rear elevation view thereof.
    FIG. 4 is a left side elevation view thereof.
    FIG. 5 is a right side elevation view thereof.
    FIG. 6 is a top plan view thereof; and,
    FIG. 7 is a bottom plan view thereof.

    Fusion protein inhibiting osteoclast formation, preparation method and medicine compositions thereof
    2.
    发明授权
    Fusion protein inhibiting osteoclast formation, preparation method and medicine compositions thereof 有权
    融合蛋白抑制破骨细胞形成，其制备方法和药物组合物

    公开(公告)号：US08460673B2

    公开(公告)日：2013-06-11

    申请号：US13123235

    申请日：2009-09-29

    申请人： Jun Bao ,  Haiming Chen ,  Daocheng Zhu

    发明人： Jun Bao ,  Haiming Chen ,  Daocheng Zhu

    IPC分类号： A61K39/00

    CPC分类号： C07K14/70575 ,  A61K38/00 ,  C07K2319/30

    摘要： The present invention provides a coding gene having the nucleic acid sequence shown as SEQ ID NO:1 and the fusion protein RIG (SEQ ID NO:2) that inhibits osteoclast formation. The present invention also provides the preparation method for the fusion protein RIG as well as synthetic oligo-nucleotide primers, plasmids and host cells used in the method and a medicine having the above fusion protein RIG as active ingredient. The fusion protein RIG in present invention is derived from humanized immunoglobulin and RANKL with a flexible hinge region. RIG can cross link the cell surface receptor RANK and Fcγ 1 to induce a cytosolic inhibitory signal leading to the inhibition of osteoclast formation. The fusion protein RIG in present invention can play an essential role in treating osteoporosis and bone resorption diseases caused by tumor metastasis.

    摘要翻译： 本发明提供具有SEQ ID NO：1所示的核酸序列和抑制破骨细胞形成的融合蛋白RIG（SEQ ID NO：2）的编码基因。 本发明还提供了融合蛋白RIG的制备方法以及该方法中使用的合成寡核苷酸引物，质粒和宿主细胞以及具有上述融合蛋白RIG作为活性成分的药物。 本发明的融合蛋白RIG衍生自具有柔性铰链区的人源化免疫球蛋白和RANKL。 RIG可以连接细胞表面受体RANK和Fcγ1以诱导细胞溶质抑制信号，导致破骨细胞形成的抑制。 本发明的融合蛋白RIG可以在治疗由肿瘤转移引起的骨质疏松症和骨吸收疾病中发挥重要作用。

    Fusion Protein Inhibiting Osteoclast Formation, Preparation Method and Medicine Compositions Thereof
    4.
    发明申请
    Fusion Protein Inhibiting Osteoclast Formation, Preparation Method and Medicine Compositions Thereof 有权
    融合蛋白抑制破骨细胞形成，制备方法和药物组合物

    公开(公告)号：US20110243944A1

    公开(公告)日：2011-10-06

    申请号：US13123235

    申请日：2009-09-29

    申请人： Jun Bao ,  Haiming Chen ,  Daocheng Zhu

    发明人： Jun Bao ,  Haiming Chen ,  Daocheng Zhu

    IPC分类号： A61K39/395 ,  C07H21/04 ,  C07K19/00 ,  C12P21/02 ,  A61P19/08 ,  A61P19/10

    CPC分类号： C07K14/70575 ,  A61K38/00 ,  C07K2319/30

    摘要： The present invention provides a coding gene having the nucleic acid sequence shown as SEQ ID NO:1 and the fusion protein RIG (SEQ ID NO:2) that inhibits osteoclast formation. The present invention also provides the preparation method for the fusion protein RIG as well as synthetic oligo-nucleotide primers, plasmids and host cells used in the method and a medicine having the above fusion protein RIG as active ingredient. The fusion protein RIG in present invention is derived from humanized immunoglobulin and RANKL with a flexible hinge region. RIG can cross link the cell surface receptor RANK and Fcγ 1 to induce a cytosolic inhibitory signal leading to the inhibition of osteoclast formation. The fusion protein RIG in present invention can play an essential role in treating osteoporosis and bone resorption diseases caused by tumor metastasis.

    摘要翻译： 本发明提供具有SEQ ID NO：1所示的核酸序列和抑制破骨细胞形成的融合蛋白RIG（SEQ ID NO：2）的编码基因。 本发明还提供了融合蛋白RIG的制备方法以及该方法中使用的合成寡核苷酸引物，质粒和宿主细胞以及具有上述融合蛋白RIG作为活性成分的药物。 本发明的融合蛋白RIG衍生自具有柔性铰链区的人源化免疫球蛋白和RANKL。 RIG可以将细胞表面受体RANK和Fcγ1交联以诱导抑制破骨细胞形成的细胞溶质抑制信号。 本发明的融合蛋白RIG可以在治疗由肿瘤转移引起的骨质疏松症和骨吸收疾病中发挥重要作用。

    Allergen vaccine proteins for the treatment and prevention of allergic diseases
    5.
    发明授权
    Allergen vaccine proteins for the treatment and prevention of allergic diseases 失效
    过敏原疫苗蛋白用于治疗和预防过敏性疾病

    公开(公告)号：US07566456B2

    公开(公告)日：2009-07-28

    申请号：US11474180

    申请日：2006-06-23

    申请人： Haiming Chen

    发明人： Haiming Chen

    IPC分类号： C07K14/00 ,  C07K17/00 ,  A61K39/00 ,  A61K39/35 ,  A61K39/36

    CPC分类号： C07K14/47 ,  A61K38/00 ,  C07K2319/30

    摘要： The present invention provides fusion proteins comprising an allergen sequence linked via an IgG hinge region to another polypeptide sequence capable of specifically binding to a native IgG inhibitory receptor containing an immune receptor tyrosine based inhibitory motif (ITIM). They are designed to cross-link an Fc receptor for IgE (e.g., FcεR1) and an IgG inhibitory receptor (e.g., FcγRIIb), thereby inhibiting the IgE-driven mediators released from mast cells and basophils. In addition, the present invention provides nucleic acid molecules encoding the fusion proteins, vectors and host cells for producing the fusion proteins, pharmaceutical compositions comprising the fusion proteins, and methods for ameliorating or reducing the risk of IgE-medicated allergic diseases.

    摘要翻译： 本发明提供融合蛋白，其包含通过IgG铰链区与能够特异性结合含有基于免疫受体酪氨酸的抑制基序（ITIM）的天然IgG抑制受体的另一多肽序列连接的变应原序列。 它们被设计成交联IgE的Fc受体（例如FcepsilonR1）和IgG抑制性受体（例如，FcγRIIb），从而抑制从肥大细胞和嗜碱性粒细胞释放的IgE驱动的介质。 此外，本发明提供编码融合蛋白的核酸分子，用于产生融合蛋白的载体和宿主细胞，包含融合蛋白的药物组合物，以及用于改善或降低IgE药物过敏性疾病风险的方法。

    Kind Of Fusion Protein, Gene Encoding It, Expression Method And Use Thereof
    6.
    发明申请
    Kind Of Fusion Protein, Gene Encoding It, Expression Method And Use Thereof 有权
    融合蛋白，基因编码，表达方法及其应用

    公开(公告)号：US20080015347A1

    公开(公告)日：2008-01-17

    申请号：US10592376

    申请日：2004-05-08

    申请人： Haiming Chen ,  Junyu Gao

    发明人： Haiming Chen ,  Junyu Gao

    IPC分类号： A61K38/00 ,  A61P43/00 ,  C07K14/00 ,  C12N15/00 ,  C12N15/11 ,  C12N5/06 ,  C12P21/04

    CPC分类号： C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2319/30 ,  Y10S530/862 ,  Y10S530/868

    摘要： This invention provides a fusion protein (FP4) and the code gene, expression method, and clinical application; its goal is to provide a fusion protein, the code gene, and the expression method as well as to take this fusion protein as the active constituent anti-allergic medicine. In addition, the invention provides the sequence of fusion protein attached on SEQ ID 2 and any derivation protein of the fusion protein (FP4) which includes adding or deleting several amino acids of SEQ ID2 as well as increasing or deducing nuclear tides of SEQ ID 1. We designed to cross-link IgE active receptor and an IgG inhibitory receptor by endogens hinge without any extraneous chemical link. This invention fusion protein has function to block the IgE acceptor, moreover fragment of fusion protein has ability to specifically bind to a native IgG inhibitory receptor containing immunoreceptor tyrosine-based inhibitory motif, thereby inhibiting the IgE-driven mediator release from mast cells and basophils. It will play important role in the allergic disease treatment.

    摘要翻译： 本发明提供融合蛋白（FP4）及其代码基因，表达方法和临床应用; 其目标是提供融合蛋白，代码基因和表达方法，并将该融合蛋白作为活性成分抗过敏药物。 此外，本发明提供了连接在SEQ ID2上的融合蛋白的序列和融合蛋白（FP4）的任何衍生蛋白，其包括添加或缺失SEQ ID2的若干个氨基酸，以及增加或推导出SEQ ID NO： 我们设计通过内源铰链交联IgE活性受体和IgG抑制受体，没有任何外来化学连接。 本发明融合蛋白具有阻断IgE受体的功能，此外，融合蛋白片段具有与含有免疫受体酪氨酸的抑制基序的天然IgG抑制受体特异性结合的能力，从而抑制IgE驱动的介体从肥大细胞和嗜碱性粒细胞释放。 它将在过敏性疾病治疗中发挥重要作用。

    Fusion protein for treatment of allergic diseases
    8.
    发明授权
    Fusion protein for treatment of allergic diseases 有权
    融合蛋白用于治疗过敏性疾病

    公开(公告)号：US07544783B2

    公开(公告)日：2009-06-09

    申请号：US10592376

    申请日：2004-05-08

    申请人： Haiming Chen ,  Junyu Gao

    发明人： Haiming Chen ,  Junyu Gao

    IPC分类号： C12P21/08

    CPC分类号： C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2319/30 ,  Y10S530/862 ,  Y10S530/868

    摘要： This invention provides a fusion protein (FP4) and the code gene, expression method, and clinical application; its goal is to provide a fusion protein, the code gene, and the expression method as well as to take this fusion protein as the active constituent anti-allergic medicine. In addition, the invention provides the sequence of fusion protein attached on SEQ ID 2 and any derivation protein of the fusion protein (FP4) which includes adding or deleting several amino acids of SEQ ID 2 as well as increasing or deducing nuclear tides of SEQ ID 1. We designed to cross-link IgE active receptor and an IgG inhibitory receptor by endogens hinge without any extraneous chemical link. This invention fusion protein has function to block the IgE acceptor, moreover fragment of fusion protein has ability to specifically bind to a native IgG inhibitory receptor containing immunoreceptor tyrosine-based inhibitory motif, thereby inhibiting the IgE-driven mediator release from mast cells and basophils. It will play important role in the allergic disease treatment.

    摘要翻译： 本发明提供融合蛋白（FP4）及其代码基因，表达方法和临床应用; 其目标是提供融合蛋白，代码基因和表达方法，并将该融合蛋白作为活性成分抗过敏药物。 此外，本发明提供了连接在SEQ ID 2上的融合蛋白的序列和融合蛋白（FP4）的任何衍生蛋白，其包括添加或缺失SEQ ID号2的几个氨基酸，以及增加或推导出SEQ ID NO 我们设计了通过内源性铰链交联IgE活性受体和IgG抑制受体，没有任何外来的化学连接。 本发明融合蛋白具有阻断IgE受体的功能，此外，融合蛋白片段具有与含有免疫受体酪氨酸的抑制基序的天然IgG抑制受体特异性结合的能力，从而抑制IgE驱动的介体从肥大细胞和嗜碱性粒细胞释放。 它将在过敏性疾病治疗中发挥重要作用。

    Allergen vaccine proteins for the treatment and prevention of allergic diseases
    9.
    发明申请
    Allergen vaccine proteins for the treatment and prevention of allergic diseases 失效

    公开(公告)号：US20060292138A1

    公开(公告)日：2006-12-28

    申请号：US11474180

    申请日：2006-06-23

    申请人： Haiming Chen

    发明人： Haiming Chen

    IPC分类号： A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C12N5/06 ,  C07K16/42

    CPC分类号： C07K14/47 ,  A61K38/00 ,  C07K2319/30

    摘要： The present invention provides fusion proteins comprising an allergen sequence linked via an IgG hinge region to another polypeptide sequence capable of specifically binding to a native IgG inhibitory receptor containing an immune receptor tyrosine based inhibitory motif (ITIM). They are designed to cross-link an Fc receptor for IgE (e.g., FcεR1) and an IgG inhibitory receptor (e.g., FcγRIIb), thereby inhibiting the IgE-driven mediators released from mast cells and basophils. In addition, the present invention provides nucleic acid molecules encoding the fusion proteins, vectors and host cells for producing the fusion proteins, pharmaceutical compositions comprising the fusion proteins, and methods for ameliorating or reducing the risk of IgE-medicated allergic diseases.